Related references
Note: Only part of the references are listed.L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies
Annalisa Pinna et al.
EXPERIMENTAL NEUROLOGY (2014)
Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: A meta-analysis
Wanqiang Chen et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease
Stewart A. Factor et al.
MOVEMENT DISORDERS (2013)
Adenosine A2A-cannabinoid CB1 receptor interaction: An integrative mechanism in striatal glutamatergic neurotransmission
Maria Teresa Tebano et al.
BRAIN RESEARCH (2012)
Therapies in Parkinson's disease
Joseph Jankovic et al.
CURRENT OPINION IN NEUROLOGY (2012)
Animal models of Parkinson's disease
Fabio Blandini et al.
FEBS JOURNAL (2012)
Comparison of polarization properties of human adult microglia and blood-derived macrophages
Bryce A. Durafourt et al.
GLIA (2012)
Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist
Zhi-Yin Lou et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2012)
Treatment with a Substance P Receptor Antagonist Is Neuroprotective in the Intrastriatal 6-Hydroxydopamine Model of Early Parkinson's Disease
Emma Thornton et al.
PLOS ONE (2012)
Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction
Nelson Rebola et al.
JOURNAL OF NEUROCHEMISTRY (2011)
Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease
Marie Therese Armentero et al.
PHARMACOLOGY & THERAPEUTICS (2011)
Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury
Shuang-Shuang Dai et al.
REVIEWS IN THE NEUROSCIENCES (2011)
Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: Effects on locomotor activity
Lyndsey E. Collins et al.
BEHAVIOURAL BRAIN RESEARCH (2010)
Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders
Tiziana Bisogno et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2010)
Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis
Kjell Fuxe et al.
CURRENT OPINION IN PHARMACOLOGY (2010)
Modulation of the endocannabinoid system: Neuroprotection or neurotoxicity?
Christopher J. Fowler et al.
EXPERIMENTAL NEUROLOGY (2010)
Caffeine Exposure and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis of Observational Studiess
Joao Costa et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Interactions between Intracellular Domains as Key Determinants of the Quaternary Structure and Function of Receptor Heteromers
Gemma Navarro et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Endocannabinoid Signaling Mediates Psychomotor Activation by Adenosine A2A Antagonists
Talia N. Lerner et al.
JOURNAL OF NEUROSCIENCE (2010)
An Engineered Zinc Finger Protein Activator of the Endogenous Glial Cell Line-Derived Neurotrophic Factor Gene Provides Functional Neuroprotection in a Rat Model of Parkinson's Disease
Josee Laganiere et al.
JOURNAL OF NEUROSCIENCE (2010)
An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A2A, dopamine D2, cannabinoid CB1, and metabotropic glutamate mGlu5 receptors
Luigi F. Agnati et al.
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION (2010)
Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice
Daniel Marcellino et al.
NEUROBIOLOGY OF DISEASE (2010)
Astrocytes and Therapeutics for Parkinson's Disease
Phillip M. Rappold et al.
NEUROTHERAPEUTICS (2010)
Treatment strategies for Parkinson's disease
Hong Yuan et al.
NEUROSCIENCE BULLETIN (2010)
The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease
J. E. Kelsey et al.
BEHAVIOURAL BRAIN RESEARCH (2009)
Cannabinoids and Parkinson's Disease
Moises Garcia-Arencibia et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2009)
Adenosine A2A receptor mediates microglial process retraction
Anna G. Orr et al.
NATURE NEUROSCIENCE (2009)
Adenosine, adenosine A2A antagonists, and Parkinson's disease
P. Jenner et al.
PARKINSONISM & RELATED DISORDERS (2009)
Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms
Liqun Yu et al.
ANNALS OF NEUROLOGY (2008)
Tremorolytic effects of adenosine A2A antagonists:: implications for parkinsonism
John D. Salamone et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Endocannabinoids mediate neuron-astrocyte communication
Marta Navarrete et al.
NEURON (2008)
The 6-hydroxydopamine model: News from the past
Fabio Blandini et al.
PARKINSONISM & RELATED DISORDERS (2008)
An improved synthesis of Rimonabant: Anti-obesity drug
Vijay Kumar Kotagiri et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2007)
Cannabinoids and neuroprotection in basal ganglia disorders
Onintza Sagredo et al.
MOLECULAR NEUROBIOLOGY (2007)
Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model
Fabio Blandini et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2007)
Peripheral inflammation and neuroprotection: Systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease
Marie-Therese Armentero et al.
NEUROBIOLOGY OF DISEASE (2006)
Targeting adenosine A2A receptors in Parkinson's disease
Michael A. Schwarzschild et al.
TRENDS IN NEUROSCIENCES (2006)
Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease
MT Armentero et al.
NEUROBIOLOGY OF DISEASE (2006)
Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease
S González et al.
BRAIN RESEARCH (2006)
Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures
GJ Kress et al.
NEUROBIOLOGY OF DISEASE (2005)
Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia
J Saura et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Adenosine receptor signaling in the brain immune system
G Haskó et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2005)
Microorlial cell activation and proliferation precedes the onset of CNS autoimmunity
ED Ponomarev et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2005)
Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine
ZL Huang et al.
NATURE NEUROSCIENCE (2005)
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTPlesioned non-human primate models of Parkinson's disease
M van der Stelt et al.
FASEB JOURNAL (2005)
Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism
E Fernandez-Espejo et al.
NEUROBIOLOGY OF DISEASE (2005)
Adenosine A3 receptor-induced CCL2 synthesis in cultured mouse astrocytes
MC Wittendorp et al.
GLIA (2004)
Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure:: Potential drugs for Parkinson's disease
J Hockemeyer et al.
JOURNAL OF ORGANIC CHEMISTRY (2004)
Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes
R Brambilla et al.
GLIA (2003)
Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration
M Karcz-Kubicha et al.
NEUROPSYCHOPHARMACOLOGY (2003)
Identification of nuclear factor 1 (NF1) as a transcriptional modulator of rat A2A adenosine receptor
YC Lee et al.
MOLECULAR BRAIN RESEARCH (2003)
A new neuromodulatory pathway with a glial contribution mediated via A2a adenosine receptors
T Nishizaki et al.
GLIA (2002)
Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets
I Lastres-Becker et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2001)
Association of coffee and caffeine intake with the risk of Parkinson disease
GW Ross et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
